GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Net Change in Cash

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Net Change in Cash : $-9.03 Mil (TTM As of Sep. 2011)


View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Poniard Pharmaceuticals's Net Change in Cash for the three months ended in Sep. 2011 was $-1.71 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2011 was $-9.03 Mil.

Poniard Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Poniard Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals Net Change in Cash Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.63 -14.81 14.81 -28.21 -14.65

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 -9.73 4.19 -1.78 -1.71

Poniard Pharmaceuticals Net Change in Cash Calculation

Poniard Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2010 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-24.276+24.025+-14.403+0
=-14.65

Poniard Pharmaceuticals's Net Change in Cash for the quarter that ended in Sep. 2011

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.708+0+0+0
=-1.71

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Net Change in Cash
Comparable Companies
BOM:506365 OBMP NSPX BOM:532041 ATRX PPCB WAR:PFM RSPI TSXV:MFS BOM:542765 HSTC CAPS ATMS AKAOQ BRTX TSXV:PBS BOM:532871 APOP TSXV:APC ONTX
Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Website
http://www.poniard.com
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines

From GuruFocus

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-12-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-09-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 3,000 Shares

By GuruFocus Research GuruFocus Editor • 08-22-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 2,000 Shares

By gurufocus • 04-06-2009